Trump’s 50% Tariff Changes Target $903 Million in Canadian Medical Equipment and Lab Products

35,000+ smart investors are already getting financial news, market signals, and macro shifts in the economy that could impact their money next with our FREE weekly newsletter. Get ahead of what the crowd finds out too late. Click Here to Subscribe for FREE.

Medical equipment has become an unexpected front in the escalating Canada-U.S. trade dispute. Starting October 30, the United States is set to apply an additional 50% tariff to newly listed Canadian products that include electrosurgical instruments and diagnostic laboratory reagents—goods used far from the auto plants at the centre of the original dispute.

The two largest health-related additions alone represented roughly $903 million in U.S. imports from Canada in 2025: about $466 million in electrosurgical instruments and $437 million in diagnostic and laboratory reagents. The change does not mean every hospital bill will suddenly jump by half, but it creates a significant new cost risk for manufacturers, distributors, laboratories and healthcare systems operating across one of the world’s most integrated borders.

Health Products Move Into the Tariff Fight

President Donald Trump signed the latest tariff modification on October 23, reshuffling the Canadian products covered by the 50% duties imposed under Section 338 of the Tariff Act of 1930. The changes take effect at 12:01 a.m. Eastern Time on October 30. The White House is removing products including certain plywood, paper and packaging goods, refrigeration equipment and machinery while adding a much broader group that includes chemicals, flooring, appliances, valves and several medical or laboratory categories.

The annex contains 100 newly covered tariff lines while removing 22. A Census-based analysis of the affected trade codes estimated that each side of the swap represented roughly $2.6 billion in 2025 U.S. imports from Canada, meaning the administration largely shifted the tariff burden instead of simply reducing it. Among the additions are diagnostic reagents, certified reference materials, electrosurgical instruments and certain scientific equipment. That combination makes healthcare one of the most economically significant new areas exposed by the reshuffle.

The $903 Million Comes From Two Major Medical Categories

The biggest new health-related category is HTS 9018.90.60, covering specified electrosurgical instruments and appliances. U.S. imports from Canada in that category were worth approximately $466 million in 2025. Canada represented roughly 10% of U.S. imports in the category, behind larger suppliers including Mexico but still making it a substantial source for equipment used in surgical and clinical settings.

The second major category is HTS 3822.19.00, covering diagnostic or laboratory reagents other than certain specifically classified malaria, Zika and blood-grouping products. Census-based trade analysis puts U.S. imports from Canada in this category at about $437 million in 2025. Together, those two lines account for roughly $903 million. Importantly, that number should not be interpreted as the total value of every healthcare-related product affected. The new list also contains certified reference materials and certain scientific instruments, so $903 million is better understood as the value of the two headline medical and laboratory categories alone.

U.S. Hospitals and Laboratories Could Bear Part of the Cost

A tariff is collected from the importer bringing a product into the United States, which means the immediate financial obligation falls on the American side of the transaction. Whether the ultimate burden stays with the importer, is absorbed by a Canadian supplier, or gets passed through to hospitals, laboratories and other customers depends on contracts, competition and the availability of substitutes. There is therefore no sound basis for assuming a 50% tariff will automatically produce a 50% increase in the final price of a medical procedure or diagnostic test.

Research nevertheless suggests that substantial portions of medical tariffs can work their way through the healthcare supply chain. A study of U.S. tariffs on medical goods found $3.4 billion in assessed duties from February through July 2025 and estimated border pass-through of 55.8%. Broader New York Federal Reserve research on the 2025 tariff increases found close to 90% pass-through into U.S. import prices. That arrives while hospitals are already managing elevated costs: the American Hospital Association reported that hospital spending on supplies increased 9.9% in 2025.

Canadian Medical Manufacturers Depend Heavily on U.S. Customers

The tariff shock matters disproportionately because the United States is by far the largest foreign market for Canadian medical devices. Canadian government industry data shows total medical-device exports rising from C$4.3 billion in 2019 to C$5.5 billion in 2024. Of the 2024 total, C$4.08 billion—or 73%—went to the United States. Germany, the United Kingdom and Belgium followed at only small fractions of that share.

That dependence is particularly relevant for smaller companies. Canada’s medical-device sector is described by Innovation, Science and Economic Development Canada as highly diversified and dominated numerically by small and medium-sized businesses. The country is also home to 137 in-vitro diagnostic companies, most of them SMEs, concentrated largely in Ontario, British Columbia and Quebec. A separate Statistics Canada analysis estimated that the broader Canadian medical-device manufacturing sector supported 88,394 full-time-equivalent positions and C$13.7 billion in total gross value added in 2023. For specialized producers, replacing a major U.S. customer base quickly may be difficult.

CUSMA Compliance Does Not Protect the Newly Listed Goods

Normally, proving that a Canadian product satisfies the rules of origin under the Canada-United States-Mexico Agreement can be enormously valuable. The Canadian Trade Commissioner Service says CUSMA preferential treatment covers more than 98% of tariff lines and more than 99.9% of bilateral Canada-U.S. trade. Section 338 is different. Both Washington and Ottawa explicitly state that Canadian goods covered by these tariffs remain subject to the additional duty even when they qualify as originating goods under CUSMA.

That distinction changes the calculation for businesses that spent years structuring North American production around preferential trade. A Canadian electrosurgical instrument cannot escape the new tariff merely because its components and manufacturing process satisfy CUSMA’s origin requirements. For an industry whose biggest export customer is the United States, that removes one of the principal protections normally associated with continental supply chains. Companies may instead have to consider pricing changes, alternative production locations, different export destinations or a reduction in U.S.-bound shipments if the additional cost cannot be absorbed commercially.

A 1930 Trade Law Is Connecting Medical Equipment to an Auto Dispute

Section 338 gives a U.S. president authority, under specified conditions, to impose additional duties of up to 50% when a foreign country is found to discriminate against or place an unequal burden on American commerce. The Trump administration invoked that authority against Canada in July, initially framing separate actions around motor vehicles, alcoholic beverages and dairy. The October medical-product additions are being made through the proclamation originally connected to the dispute over Canadian treatment of U.S. automobiles and auto parts.

That helps explain an otherwise unusual feature of the latest move: the tariff targets do not have to resemble the products at the centre of the underlying complaint. Laboratory reagents and surgical instruments are appearing in an action justified by the administration through its motor-vehicle dispute with Canada. The White House says the changing product lists are intended to offset disadvantages to U.S. commerce while serving the public interest. Because Section 338 also permits a proclamation to be supplemented or amended, the composition of the tariff list has already become fluid rather than fixed.

Medical Tariffs Arrived as Other U.S. Industries Won Relief

The October change is particularly striking because it simultaneously provides relief to businesses in other sectors. Plywood sheets, corrugated packaging, plastic crates, refrigeration equipment and some machinery are among the goods being removed from the 50% tariff list. Republican Senator Susan Collins of Maine had pressed administration officials for relief, arguing that farmers and other businesses in her state depended on specialized Canadian products that could be unavailable or significantly more expensive from alternative suppliers.

The Associated Press and Reuters reported that the announcement came as Collins faced a difficult reelection contest ahead of the November 3 midterm elections. The White House described the modification as an effort to better serve the public interest. Whatever the political motivation, the economic effect is clear: tariff exposure has been redistributed rather than eliminated. American agricultural and packaging users gained relief on some Canadian products while importers of diagnostic reagents, electrosurgical equipment and other newly listed goods inherited a new 50% duty risk.

Ottawa Is Assessing the Changes After Already Retaliating Once

Canada was already deep into a cycle of retaliation before medical products appeared on the latest U.S. list. The federal government announced countermeasures in August after Washington imposed 50% tariffs on C$27.6 billion worth of Canadian goods. Canada’s response, which took effect September 8, applied tariffs of 15%, 25% or 50% to selected U.S. products, with Ottawa saying it would match the American measures dollar for dollar and generally rate for rate.

The immediate Canadian response to the October 23 revision was more restrained. Trade Minister Dominic LeBlanc said Ottawa was assessing the changes rather than immediately announcing another round of counter-tariffs. His government has continued to say it is prepared to engage constructively with Washington if an agreement can protect Canadian interests and sovereignty. The challenge is that another escalation could impose additional costs on businesses on both sides of the border. For Canadian medtech exporters, however, waiting for diplomacy also means preparing for a 50% U.S. duty that is scheduled to begin within days.

The October 30 Deadline Makes Product Classification Critical

For companies shipping affected goods, the most important date is October 30. The proclamation applies the revised tariff treatment to Canadian products entered for consumption, or withdrawn from warehouse for consumption, from 12:01 a.m. Eastern Time that day. The government annex also warns that its plain-language product descriptions are informational; the legal scope ultimately turns on the Harmonized Tariff Schedule classifications. A product that sounds medically similar to a listed item is not automatically covered, while one falling squarely within a listed HTS provision may be.

Importers, customs brokers and Canadian exporters therefore have a narrow window to review classifications, entry dates and existing supply arrangements. Previous U.S. Customs and Border Protection guidance for the Section 338 measures has required affected imports to be reported using designated Chapter 99 tariff provisions alongside the underlying commodity classification. Further technical implementation instructions can still matter. The $903 million figure provides a useful picture of the trade exposed in 2025, but future shipments could change quickly as companies renegotiate contracts, alter sourcing or wait to see whether the tariff list is modified again.

This Options Discord Chat is The Real Deal

While the internet is scoured with trading chat rooms, many of which even charge upwards of thousands of dollars to join, this smaller options trading discord chatroom is the real deal and actually providing valuable trade setups, education, and community without the noise and spam of the larger more expensive rooms. With a incredibly low-cost monthly fee, Options Trading Club (click here to see their reviews) requires an application to join ensuring that every member is dedicated and serious about taking their trading to the next level. If you are looking for a change in your trading strategies, then click here to apply for a membership.